China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class ASZSE: 000999

China Resources Sanjiu Medical & Pharmaceutical Co: Revenue up 4.99% but net profit down 24.31% as Tasly acquisition reshapes business

· Issued by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A

Revenue grew 4.99% year-over-year to ¥14.81 billion, but net profit fell 24.31% due to a high base and Tasly consolidation. The company completed a major acquisition, expanded its R&D pipeline, and proposed a ¥4.5 per 10 shares interim dividend.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A

All China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A news releases